Verition Fund Management
GPCR icon

Verition Fund Management’s Structure Therapeutics GPCR Stock Holding History

Verition Fund Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,700
Closed -$201K – 3095
2024
Q1 		$201K Buy
+4,700
New +$198K ﹤0.01% 2500

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Verition Fund Management's GPCR Position: Q1 2026 in Review

Verition Fund Management reduced its Structure Therapeutics (GPCR) stake by 64% in Q1 2026, selling an estimated $3.43M and leaving 28,074 shares worth $1.35M. The position accounts for 0.01% of the portfolio, ranked #1189.

Verition Fund Management first reported a position in GPCR in Q2 2024 and has held it in 7 quarters since. The position peaked at $5.44M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Verition Fund Management held 28,074 shares of Structure Therapeutics worth $1.35M as of Q1 2026.
  • Verition Fund Management sold 50,075 Structure Therapeutics shares in Q1 2026, an estimated $3.43M.
  • Structure Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q1 2026, its #1189 holding.
  • Verition Fund Management first reported a position in Structure Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Verition Fund Management's Structure Therapeutics position peaked at $5.44M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.